Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 1/31/2019 |
| Start Date: | January 2016 |
| End Date: | August 2019 |
| Contact: | Edward T Van matre, PharmD |
| Email: | edward.vanmatre@ucdenver.edu |
This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients
who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development
of augmented renal clearance and the effects and duration of effects this may have on
levetiracetam clearance.
who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development
of augmented renal clearance and the effects and duration of effects this may have on
levetiracetam clearance.
Inclusion Criteria:
- Patients diagnosed with non-traumatic subarachnoid hemorrhage requiring levetiracetam
for seizure prophylaxis or treatment
- Presentation to University of Colorado Hospital within 48 hours of subarachnoid
hemorrhage
- Adults ages 18 to 89 years
- Anticipated length of stay ≥ 48 hours
- Informed consent provided by the patient or patient's designated medical proxy
Exclusion Criteria:
- Pregnancy
- Patients receiving renal replacement therapy
- Brain death or imminent brain death expected ≤48 hours
- Patient with history of nephrectomy or renal transplant
We found this trial at
1
site
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Phone: 720-848-6964
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
